vs
Cronos Group Inc.（CRON）与Niagen Bioscience, Inc.（NAGE）财务数据对比。点击上方公司名可切换其他公司
Cronos Group Inc.的季度营收约是Niagen Bioscience, Inc.的1.3倍（$44.5M vs $33.8M）。Niagen Bioscience, Inc.净利率更高（12.2% vs -4.1%，领先16.3%）。Cronos Group Inc.同比增速更快（47.0% vs 16.2%）。过去两年Cronos Group Inc.的营收复合增速更高（32.7% vs 23.6%）
Cronos集团是全球性大麻素企业，主营大麻种植、加工及相关衍生产品的分销业务，产品线覆盖健康补充剂、快消品及医用大麻品类，主要服务北美、欧洲、亚太地区的合规娱乐与医用消费市场，严格遵循各地监管要求保障产品品质。
Niagen Bioscience（原名为ChromaDex）是一家成立于1999年，总部位于加利福尼亚州洛杉矶的生物科技公司。公司业务涵盖标准品、膳食补充剂以及原料技术开发多个领域，目前在纳斯达克挂牌上市。
CRON vs NAGE — 直观对比
营收规模更大
CRON
是对方的1.3倍
$33.8M
营收增速更快
CRON
高出30.8%
16.2%
净利率更高
NAGE
高出16.3%
-4.1%
两年增速更快
CRON
近两年复合增速
23.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $44.5M | $33.8M |
| 净利润 | $-1.8M | $4.1M |
| 毛利率 | 36.4% | 64.1% |
| 营业利润率 | -16.8% | 12.1% |
| 净利率 | -4.1% | 12.2% |
| 营收同比 | 47.0% | 16.2% |
| 净利润同比 | -104.2% | -42.4% |
| 每股收益（稀释后） | $-0.01 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRONNAGE
| Q4 25 | $44.5M | $33.8M | ||
| Q3 25 | $36.3M | $34.0M | ||
| Q2 25 | $33.5M | $31.1M | ||
| Q1 25 | $32.3M | $30.5M | ||
| Q4 24 | $30.3M | $29.1M | ||
| Q3 24 | $34.3M | $25.6M | ||
| Q2 24 | $27.8M | $22.7M | ||
| Q1 24 | $25.3M | $22.2M |
净利润CRONNAGE
| Q4 25 | $-1.8M | $4.1M | ||
| Q3 25 | $26.0M | $4.6M | ||
| Q2 25 | $-39.7M | $3.6M | ||
| Q1 25 | $6.1M | $5.1M | ||
| Q4 24 | $43.7M | $7.2M | ||
| Q3 24 | $8.3M | $1.9M | ||
| Q2 24 | $-8.8M | $-15.0K | ||
| Q1 24 | $-2.2M | $-492.0K |
毛利率CRONNAGE
| Q4 25 | 36.4% | 64.1% | ||
| Q3 25 | 50.4% | 64.5% | ||
| Q2 25 | 43.4% | 65.0% | ||
| Q1 25 | 42.6% | 63.4% | ||
| Q4 24 | 35.7% | 62.5% | ||
| Q3 24 | 10.5% | 63.5% | ||
| Q2 24 | 22.7% | 60.2% | ||
| Q1 24 | 17.7% | 60.7% |
营业利润率CRONNAGE
| Q4 25 | -16.8% | 12.1% | ||
| Q3 25 | -1.4% | 12.5% | ||
| Q2 25 | -15.9% | 10.2% | ||
| Q1 25 | -12.6% | 15.7% | ||
| Q4 24 | -37.5% | 24.4% | ||
| Q3 24 | -98.2% | 6.3% | ||
| Q2 24 | -56.1% | -1.1% | ||
| Q1 24 | -63.1% | -3.3% |
净利率CRONNAGE
| Q4 25 | -4.1% | 12.2% | ||
| Q3 25 | 71.4% | 13.5% | ||
| Q2 25 | -118.7% | 11.6% | ||
| Q1 25 | 19.0% | 16.6% | ||
| Q4 24 | 144.3% | 24.6% | ||
| Q3 24 | 24.4% | 7.3% | ||
| Q2 24 | -31.5% | -0.1% | ||
| Q1 24 | -8.9% | -2.2% |
每股收益（稀释后）CRONNAGE
| Q4 25 | $-0.01 | $0.05 | ||
| Q3 25 | $0.07 | $0.05 | ||
| Q2 25 | $-0.10 | $0.04 | ||
| Q1 25 | $0.02 | $0.06 | ||
| Q4 24 | $0.12 | $0.10 | ||
| Q3 24 | $0.02 | $0.02 | ||
| Q2 24 | $-0.02 | $0.00 | ||
| Q1 24 | $-0.01 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $831.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $76.5M |
| 总资产 | $1.2B | $106.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRONNAGE
| Q4 25 | $831.8M | — | ||
| Q3 25 | $824.2M | $64.1M | ||
| Q2 25 | $834.4M | $60.3M | ||
| Q1 25 | $837.8M | $55.5M | ||
| Q4 24 | $858.8M | $44.5M | ||
| Q3 24 | $862.0M | $32.2M | ||
| Q2 24 | $848.2M | $27.7M | ||
| Q1 24 | $855.1M | $27.4M |
股东权益CRONNAGE
| Q4 25 | $1.1B | $76.5M | ||
| Q3 25 | $1.1B | $70.7M | ||
| Q2 25 | $1.1B | $64.2M | ||
| Q1 25 | $1.1B | $55.3M | ||
| Q4 24 | $1.1B | $46.1M | ||
| Q3 24 | $1.1B | $34.4M | ||
| Q2 24 | $1.1B | $30.7M | ||
| Q1 24 | $1.1B | $29.0M |
总资产CRONNAGE
| Q4 25 | $1.2B | $106.4M | ||
| Q3 25 | $1.2B | $98.1M | ||
| Q2 25 | $1.2B | $91.5M | ||
| Q1 25 | $1.2B | $81.3M | ||
| Q4 24 | $1.2B | $68.3M | ||
| Q3 24 | $1.2B | $56.5M | ||
| Q2 24 | $1.1B | $54.0M | ||
| Q1 24 | $1.1B | $54.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $679.0K |
| 自由现金流经营现金流 - 资本支出 | $9.7M | — |
| 自由现金流率自由现金流/营收 | 21.8% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | 0.16× |
| 过去12个月自由现金流最近4个季度 | $149.0K | — |
8季度趋势，按日历期对齐
经营现金流CRONNAGE
| Q4 25 | $11.8M | $679.0K | ||
| Q3 25 | $13.3M | $3.7M | ||
| Q2 25 | $2.8M | $1.3M | ||
| Q1 25 | $-2.1M | $7.9M | ||
| Q4 24 | $7.7M | $8.6M | ||
| Q3 24 | $11.6M | $3.5M | ||
| Q2 24 | $1.7M | $-264.0K | ||
| Q1 24 | $-2.2M | $295.0K |
自由现金流CRONNAGE
| Q4 25 | $9.7M | — | ||
| Q3 25 | $8.8M | — | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $4.2M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $-3.9M | — |
自由现金流率CRONNAGE
| Q4 25 | 21.8% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | -53.8% | — | ||
| Q4 24 | 13.8% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -15.5% | — |
资本支出强度CRONNAGE
| Q4 25 | 4.8% | — | ||
| Q3 25 | 12.3% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | 47.3% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 18.7% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 6.8% | — |
现金转化率CRONNAGE
| Q4 25 | — | 0.16× | ||
| Q3 25 | 0.51× | 0.81× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | -0.34× | 1.56× | ||
| Q4 24 | 0.18× | 1.20× | ||
| Q3 24 | 1.39× | 1.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRON
| Cannabis Flower | $33.7M | 76% |
| Cannabis Extracts | $10.8M | 24% |
NAGE
| TRUNIAGEN Consumer Product | $27.5M | 81% |
| Ingredients Segment | $5.7M | 17% |
| Other | $694.0K | 2% |
